Monitoring glucose levels in diabetes patients on dialysis
Real-World Evaluation of Continuous Glucose Monitoring Data in People With Diabetes and End-Stage Renal Disease Receiving Dialysis
University of Nottingham · NCT06657508
This study tests how dialysis affects blood sugar levels in people with diabetes who use continuous glucose monitors to see if there are any patterns or long-term health impacts.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Nottingham (other) |
| Locations | 1 site (Derby) |
| Trial ID | NCT06657508 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate glucose fluctuations in individuals with insulin-treated diabetes mellitus who are undergoing dialysis. By utilizing continuous glucose monitoring (CGM) over a two-week period, the study will assess how dialysis impacts glucose levels during and between sessions. Additionally, it will explore the relationship between glucose trends and fluid level changes, as well as long-term clinical outcomes such as hospital admissions. The study focuses on existing users of NHS-funded CGM in the UK.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with insulin-treated diabetes and end-stage renal disease on dialysis.
Not a fit: Patients with a life expectancy of less than three months or those participating in competing studies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve glucose management and health outcomes for diabetes patients on dialysis.
How similar studies have performed: While continuous glucose monitoring is standard care for diabetes, this specific approach in dialysis patients is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Age: ≥18 years (no upper age limit) * People with insulin-treated diabetes who receive NHS funded continuous glucose monitoring as part of their routine clinical care * Diabetes duration \> 6 months * People with end-stage renal disease established on dialysis (maintenance haemodialysis or peritoneal dialysis) * Ability to give informed consent Exclusion criteria: * Participation in other competing studies/clinical trials as determined by the study investigator * Serious illness or events with life expectancy \< 3 months or other significant illness which, in the opinion of the study clinician, precludes involvement
Where this trial is running
Derby
- University Hospitals of Derby and Burton — Derby, United Kingdom (RECRUITING)
Study contacts
- Study coordinator: Emma Wilmot
- Email: emma.wilmot@nottingham.ac.uk
- Phone: 0044 1332 258268
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Diabetes Mellitus, End-Stage Renal Disease, Diabetes mellitus, End-stage renal disease, End-stage kidney disease, Dialysis, Haemodialysis, Peritoneal dialysis